Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in philadelphia chromosome-positive chronic myeloid leukemia

Thyroid

Volumn 20, Issue 11, 2010, Pages 1209-1214

  Kim, Theo D ^a   Schwarz, Michaela ^a   Nogai, Hendrik ^a   Grille, Peggy ^a   Westermann, Jörg ^a   Plöckinger, Ursula ^a   Braun, Doreen ^a   Schweizer, Ulrich ^a   Arnold, Renate ^a   Dörken, Bernd ^a   Le Coutre, Philipp ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DASATINIB; FREE TRIIODOTYRONINE; IMATINIB; LEVOTHYROXINE; NILOTINIB; THIAMAZOLE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE THYROIDITIS; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; FREE THYROXINE INDEX; GOITER; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBTOTAL THYROIDECTOMY; THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID GLAND;

EID: 78249244171     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0251     Document Type: Article

References (34)

1. Hershman JM, Liwanpo L 2010 How does sunitinib cause hypothyroidism? Thyroid 20:243-244.
2. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P 2009 Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331-336.
3. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219-228.
4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664.
5. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83.
6. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schoffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454.
7. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent) - induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149.
8. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672.
9. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355.
10. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534.
11. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schoffski P 2010 Shrinkage of thyroid volume in sunitinibtreated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317-322.
12. Makita N, Miyakawa M, Fujita T, Iiri T 2010 Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20:323-326.
13. Wolter P, Stefan C, Decallonne B, Dumez H, Fieuws S, Wildiers H, Clement P, Debaere D, Van Oosterom A, Schoffski P 2008 Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol (Meeting Abstracts) 26:5126.
14. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI 2008 Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268. (Pubitemid 351201706)
15. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42.
16. Druker BJ 2008 Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808-4817.
17. Hehlmann R, Hochhaus A, Baccarani M 2007 Chronic myeloid leukaemia. Lancet 370:342-350.
18. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA 2009 Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061.
19. Hantschel O, Rix U, Superti-Furga G 2008 Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 49:615-619.
20. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD 2007 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345-356.
21. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D 2010 Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453.
22. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141.
23. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401.
24. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG 2006 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551. (Pubitemid 43882350)
25. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL 2006 Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541. (Pubitemid 43882349)
26. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM 2010 Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259.
27. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M 2010 Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270.
28. Kim TD, Dörken B, le Coutre P 2008 Nilotinib for the treatment of chronic myeloid leukemia. Expert Rev. Hematol 1:29-39.
29. Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH 1990 American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 263:1529-1532.
30. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228-238.
31. de Groot JW, Links TP, van der Graaf WT 2006 Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17:1719-1720.
32. de Groot JW, Zonnenberg BA, Plukker JT, van der Graaf WT, Links TP 2005 Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78:433-438.
33. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE 2007 A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469.
34. Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, Maia AL 2008 Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 158:771-772.